Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients

Bone Marrow Transplantation

Volumn 23, Issue 3, 1999, Pages 283-290

  Tollemar, J ^a   Gross, N ^a   Dolgiras, N ^a   Jarstrand, C ^a   Ringden O ^a   Hammarstrom L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic BMT; Bovine anti Candida antibodies; Fungal prophylaxis; Oral administration

Indexed keywords

FUNGUS ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANDIDA; CANDIDIASIS; CHILD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; SALIVA; SCHOOL CHILD;

EID: 0032991610     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701560     Document Type: Article

References (41)

1. Tollemar J, Ringden O, Boström LS et al. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635-641.
2. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17 (Suppl. 6): 10-13.
3. Bowden RA, Meyers JD. Infectious complications in bone marrow transplantation. In: RH Rubin, LS Young (eds). Clinical Approach to Infection in the Compromised Host. Plenum: New York, 1994, pp 601-625.
4. Eklöf Andström E, Ringdén O, Remberger M et al. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996; 39: 185-193.
5. Winston DJ, Gale RP, Meyer DV, Young LS. Infectious complications of human bone marrow transplantation. Medicine 1979; 58: 1-31.
6. Shah PM, Just KG. Fungal infections in organ transplantation. In: Holmberg K, Meyer R (eds). Diagnosis and Therapy of Systemic Fungal Infections. Raven Press: New York, 1989, pp 71-78.
7. Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
8. Meunier F. Prevention of mycoses in immunocompromised patients. Rev Inf Dis 1987; 2: 408-416.
9. Odds FC. Candida and Candidosis. A Review and Bibliography. Balliére Tindall: London, 1988.
10. Hay RJ. Dimorphism and candidosis: clinical and therapeutic implications. Diagnosis and treatment of mycoses. In: van den Bossche H, Odds FC, Kerridge D (eds). Dimorphic Fungi in Biology and Medicine. Plenum Press: New York, 1993, pp 373-379.
11. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
12. Hammarström L, Gardulf A, Hammarström V et al. Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev 1994; 139: 43-70.
13. Copelan EA, Bechtel T, Featheringham NC et al. Oral administration of IgG in marrow transplant recipients. Drug Intell Clin Pharm 1988; 22: 912.
14. Tutschka PJ. The use of immunoglobulin in bone marrow transplantation. J Clin Immunol 1990; 10: 88-92.
15. Weiner C, Pan Q, Casswall T et al. Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol (submitted).
16. Faber V. Cows make antibodies against AIDS infections. New Scientist 1988; 35.
17. Ringdén O, Ruutu T, Remberger M et al for the Nordic Bone Marrow Transplantation Group. A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia. A report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
18. Ringdén O. Allogeneic bone marrow transplantation for hematological malignancies - controversies and recent advances. Acta Oncol 1997; 36: 549-564.
19. Meistner H, Heymer M, Schäfer H, Haferkamp O. Role of Candida albicans in granulomatous tissue reactions. J Infect Dis 1977; 135: 224-234.
20. Bogstedt AK, Robertson AK, Hammarström L. Survival of immunoglobulins from different species through the gastrointestinal passage of healthy adult volunteers: implications for human therapy. Antimicrob Agents Chemother 1997; 41: 2320.
21. Wingard JR, Merz WG, Rinaldi MG. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991; 325: 1274-1277.
22. Cameron ML, Schell WA, Bruch S et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993; 37: 2449-2453.
23. Como JA, Dismukes WE. Drug therapy. New Engl J Med 1994; 330: 263-272.
24. Schimpff SC, Greene WH, Young VM et al. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975; 82: 351-358.
25. Tzipori S, Robertson D, Chapman C. Remission of diarrhea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum. Br Med J 1986; 293: 1276-1277.
26. Tzipori S, Roberton D, Cooper DA, White L. Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum. Lancet 1987; 2: 344-345.
27. Ungar BLP, Ward DJ, Fayer R, Quinn CA. Cessation of cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. Gastroenterology 1990; 98: 486-489.
28. Nord J, Pearl M, DiJohn D et al. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS 1990; 4: 581-584.
29. Greenberg PD, Cello JP. Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J AIDS Hum Retrovir 1996; 13: 348-354.
30. Shield J, Melville C, Novelli V et al. Bovine colostrum immunoglobulin concentrate for cryptosporidiosis in AIDS. Arch Dis Child 1993; 69: 451-453.
31. Rump JA, Arndt R, Arnold A et al. Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum. Clin Invest 1992; 70: 588-594.
32. Plettenberg A, Stoehr A, Stellbrink H-J et al. A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea. Clin Invest 1993; 71: 42-45.
33. Lavö B, Knutson F. Knutson L et al. Jejunal secretion of secretory immunoglobulins and gliadin antibodies in celiac disease. Dig Dis Sci 1992; 37: 53-59.
34. Eibl MM, Wolf HM, Fürnkranz H, Rosenkranz, A. Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. New Engl J Med 1988; 319: 1-7.
35. Tacket CO, Losonsky G, Link H et al. Protection by milk immunoglobulin concentrate against oral challange with enterotoxigenic Escherichia coli. New Engl J Med 1988; 318: 1240-1243.
36. Schaller JP, Saif LJ, Cordle CT et al. Prevention of human rotavirus-induced diarrhea in gnotobiotic piglets using bovine antibody. J Infect Dis 1992; 165: 623-630.
37. Tjellström B, Stenhammar L, Eriksson S, Magnusson K-E. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 1993; 341: 701-702.
38. Hammarström V, Smith CIE, Hammarström L. Oral immunoglobulin treatment in Campylobacter jejuni enteritis. Lancet 1993; 341: 1036.
39. Mitra AK, Mahalanabis D, Ashraf H et al. Hyperimmune cow colostrum reduces diarrhea due to rotavirus: a double-blind, controlled clinical trial. Acta Paediatr 1995; 84: 996-1001.
40. Janson A, Nava S, Brüssow H et al. Titers of specific antibodies in immunised and non-immunised cow colostrum. Implications for their use in patients with gastro-intestinal infections. In: Björck L, Mullen M, Korhonen H et al (eds). Indigenous Antimicrobial Agents of Milk - Recent Developments. International Dairy Federation Press 1994; 221-228.
41. Butler JEB. Bovine immunoglobulins: an augmented review. Vet Immunol Immunopathol 1983; 4: 43-52.